We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Read MoreHide Full Article
Key Takeaways
CVS posted Q1 adjusted EPS of $2.57 and revenues of $100.43B; shares rose 4.8% pre-market.
CVS' Health Services revenues rose 11% to $48.24B, while Health Care Benefits grew 3.3% to $35.97B.
CVS' operating income rose 38.7% to $4.68B as gross margin hit 15.6%; 2026 EPS view raised to $7.30-$7.50.
CVS Health Corporation (CVS - Free Report) delivered first-quarter 2026 adjusted earnings of $2.57 per share, up 14.2% from the year-ago quarter. The figure beat the Zacks Consensus Estimate of $2.21 by 16.38%.
Total revenues rose 6.2% year over year to $100.43 billion, topping the consensus mark of $94.37 billion by 6.41%. Operating execution improved across the enterprise, while days claims payable ended the quarter at 42.9 days.
Following the announcement, CVS shares climbed 4.8% in the pre-market session today.
CVS Posts Higher Revenues on Broad Segment Gains
CVS generated revenue growth across all three operating segments in the first quarter. Health Services remained the largest contributor, with segment revenues of $48.24 billion, up 11% year over year, reflecting pharmacy drug mix and brand inflation.
Health Care Benefits revenues increased 3.3% to $35.97 billion, supported by strength in the Government business. Pharmacy & Consumer Wellness revenues were essentially flat at $31.99 billion, as prescription growth and mix benefits were largely offset by regulatory-related price reductions and reimbursement pressure.
CVS Health Expands Consolidated Margins on Operating Leverage
CVS Health’s consolidated profitability improved as operating income rose faster than the top line. Operating income increased 38.7% year over year to $4.68 billion, supported by higher segment contributions and the absence of items recorded in the prior-year period.
CVS Health Corporation Price, Consensus and EPS Surprise
From a margin standpoint, gross profit (total revenues less cost of products sold and health care costs) increased to $15.62 billion from $14.40 billion a year ago. Gross margin expanded 40 basis points (bps) to 15.6%, while operating margin improved 110 bps to 4.7%.
Adjusted operating income rose 12.5% to $5.15 billion. Adjusted operating margin also improved 30 bps year over year, reaching 5.1%, aided by lower operating expenses of $10.94 billion compared with $11.02 billion last year.
CVS Health ended the quarter with cash and cash equivalents of $9.54 billion, up from $8.45 billion at year-end 2025. Net cash provided by operating activities was $4.25 billion in the first quarter, supporting capital returns and balance sheet actions.
During the quarter, the company repaid $1.52 billion of long-term debt and paid $847 million in dividends. Long-term debt stood at $60.53 billion as of March 31, 2026, leaving continued deleveraging and disciplined capital deployment as important watch items alongside the operating recovery underway across the portfolio.
CVS Raises 2026 Outlook as Costs Stay Elevated
Management raised full-year 2026 targets following the quarter’s performance. CVS lifted its GAAP diluted earnings per share outlook to a range of $6.24-$6.44 (previously $5.94-$6.14) and boosted adjusted earnings guidance to the band of $7.30-$7.50 (earlier $7.00-$7.20). Going by the Zacks Consensus Estimate, adjusted EPS for 2026 is forecasted at $7.14.
Meanwhile, revenues for the year are projected to be at least $405 billion. The Zacks Consensus Estimate for the same stands at $406.01 billion.
The company also increased its cash flow from operations outlook to at least $9.5 billion (earlier at least $9.0 billion). CVS said that the update reflects increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments while maintaining a cautious view for the remainder of the year, given elevated cost trends and potential macro headwinds.
Our Take on CVS Stock
CVS Health exited the first quarter of 2026 on a solid note, with both earnings and revenues beating the respective estimates. Health Care Benefit revenues gained from the strong underlying performance of the Government business and also delivered the sharpest profitability improvement of the quarter. In Health Services, the company continued to post strong top-line momentum.
Within Pharmacy & Consumer Wellness, growth in prescriptions filled was aided by incremental volume tied to CVS Health’s Rite Aid asset acquisitions completed in the third quarter of 2025. The segment’s growth was weighed down by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure.
Also, the expansion of both margins in the quarter and the raised full-year guidance are highly promising for the stock.
CVS’ Zacks Rank & Key Picks
CVS Health currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.
LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Key Takeaways
CVS Health Corporation (CVS - Free Report) delivered first-quarter 2026 adjusted earnings of $2.57 per share, up 14.2% from the year-ago quarter. The figure beat the Zacks Consensus Estimate of $2.21 by 16.38%.
Total revenues rose 6.2% year over year to $100.43 billion, topping the consensus mark of $94.37 billion by 6.41%. Operating execution improved across the enterprise, while days claims payable ended the quarter at 42.9 days.
Following the announcement, CVS shares climbed 4.8% in the pre-market session today.
CVS Posts Higher Revenues on Broad Segment Gains
CVS generated revenue growth across all three operating segments in the first quarter. Health Services remained the largest contributor, with segment revenues of $48.24 billion, up 11% year over year, reflecting pharmacy drug mix and brand inflation.
Health Care Benefits revenues increased 3.3% to $35.97 billion, supported by strength in the Government business. Pharmacy & Consumer Wellness revenues were essentially flat at $31.99 billion, as prescription growth and mix benefits were largely offset by regulatory-related price reductions and reimbursement pressure.
CVS Health Expands Consolidated Margins on Operating Leverage
CVS Health’s consolidated profitability improved as operating income rose faster than the top line. Operating income increased 38.7% year over year to $4.68 billion, supported by higher segment contributions and the absence of items recorded in the prior-year period.
CVS Health Corporation Price, Consensus and EPS Surprise
CVS Health Corporation price-consensus-eps-surprise-chart | CVS Health Corporation Quote
From a margin standpoint, gross profit (total revenues less cost of products sold and health care costs) increased to $15.62 billion from $14.40 billion a year ago. Gross margin expanded 40 basis points (bps) to 15.6%, while operating margin improved 110 bps to 4.7%.
Adjusted operating income rose 12.5% to $5.15 billion. Adjusted operating margin also improved 30 bps year over year, reaching 5.1%, aided by lower operating expenses of $10.94 billion compared with $11.02 billion last year.
CVS Health’s Cash Build Offsets Ongoing Debt Obligations
CVS Health ended the quarter with cash and cash equivalents of $9.54 billion, up from $8.45 billion at year-end 2025. Net cash provided by operating activities was $4.25 billion in the first quarter, supporting capital returns and balance sheet actions.
During the quarter, the company repaid $1.52 billion of long-term debt and paid $847 million in dividends. Long-term debt stood at $60.53 billion as of March 31, 2026, leaving continued deleveraging and disciplined capital deployment as important watch items alongside the operating recovery underway across the portfolio.
CVS Raises 2026 Outlook as Costs Stay Elevated
Management raised full-year 2026 targets following the quarter’s performance. CVS lifted its GAAP diluted earnings per share outlook to a range of $6.24-$6.44 (previously $5.94-$6.14) and boosted adjusted earnings guidance to the band of $7.30-$7.50 (earlier $7.00-$7.20). Going by the Zacks Consensus Estimate, adjusted EPS for 2026 is forecasted at $7.14.
Meanwhile, revenues for the year are projected to be at least $405 billion. The Zacks Consensus Estimate for the same stands at $406.01 billion.
The company also increased its cash flow from operations outlook to at least $9.5 billion (earlier at least $9.0 billion). CVS said that the update reflects increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments while maintaining a cautious view for the remainder of the year, given elevated cost trends and potential macro headwinds.
Our Take on CVS Stock
CVS Health exited the first quarter of 2026 on a solid note, with both earnings and revenues beating the respective estimates. Health Care Benefit revenues gained from the strong underlying performance of the Government business and also delivered the sharpest profitability improvement of the quarter. In Health Services, the company continued to post strong top-line momentum.
Within Pharmacy & Consumer Wellness, growth in prescriptions filled was aided by incremental volume tied to CVS Health’s Rite Aid asset acquisitions completed in the third quarter of 2025. The segment’s growth was weighed down by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure.
Also, the expansion of both margins in the quarter and the raised full-year guidance are highly promising for the stock.
CVS’ Zacks Rank & Key Picks
CVS Health currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.
LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.